Impact BioMedical Inc.
IBOEarnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 7, 2026 | $-0.13 | — | $3.0K | — |
| May 12, 2026 | $-0.02 | — | $7.0K | — |
| Mar 27, 2026 | $0.63 | — | $7.0K | — |
| Nov 7, 2025 | $-0.12 | — | $18.0K | — |
| Aug 14, 2025 | $-1.18 | — | $7.0K | — |
| May 14, 2025 | $-0.11 | — | — | — |
| Mar 28, 2025 | $-0.42 | — | — | — |
| Nov 12, 2024 | $4.67 | — | — | — |
News
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley's Bio Labs Limited) (“Z…
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share…
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company's Common Stock will continue to trade on the NYSE Am…